A Phase I/II Trial of Sorafenib and CCI-779 in Combination With Recurrent Glioblastoma.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 11 Jun 2015
At a glance
- Drugs Temsirolimus (Primary) ; Sorafenib
- Indications Astrocytoma; Glioblastoma; Gliosarcoma
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 31 May 2013 Interim results (n=44) presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
- 31 May 2013 Primary endpoint 'Progression-free-survival-rate' has not been met.
- 26 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.